Evidence map›Paper›PMID 34699042›Full record

ReviewFolia microbiologica2021

Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?

Khalid Mehmood, Afrasim Moin, Talib Hussain, Syed Mohd Danish Rizvi, D V Gowda, Shazi Shakil, M A Kamal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Folia microbiologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Synthesis and Functions of Resistant Starch.Advances in nutrition (Bethesda, Md.) · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Khalid MehmoodDepartment of Pharmaceutics, College of Pharmacy, University of Hail, Hail, KSA, Saudi Arabia.
Afrasim MoinDepartment of Pharmaceutics, College of Pharmacy, University of Hail, Hail, KSA, Saudi Arabia.
Talib HussainDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, KSA, Saudi Arabia.
Syed Mohd Danish RizviDepartment of Pharmaceutics, College of Pharmacy, University of Hail, Hail, KSA, Saudi Arabia. sm.danish@uoh.edu.sa.ORCID http://orcid.org/0000-0002-3106-4707
D V GowdaDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, India.
Shazi ShakilKing Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
M A KamalKing Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
University of Ha'il · SAKing Abdulaziz University · SAAbbottabad University of Science and Technology · PKJSS Academy of Higher Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advancement in manipulation techniques of gut microbiota either ex vivo or in situ has broadened its plausible applicability for treating various diseases including cardiovascular disease. Several reports suggested that altering gut microbiota composition is an effective way to deal with issues associated with managing cardiovascular diseases. However, actual translation of gut microbiota manipulation-based techniques into cardiovascular-therapeutic approach is still questionable. This review summarized the evidence on challenges, opportunities, recent development, and future prospects of gut microbiota manipulation for targeting cardiovascular diseases. Initially, issues associated with current cardiovascular diseases treatment strategy, association of gut microbiota with cardiovascular disease, and its influence on cardiovascular drugs were discussed, followed by applicability of gut microbiota manipulation as a cardiovascular disease intervention strategy along with its challenges and future prospects. Despite the fact that the gut microbiota is rugged, interventions like probiotics, prebiotics, synbiotics, fecal microbiota transplantation, fecal virome transplantation, antibiotics, diet changes, and exercises could manipulate it. Advanced techniques like administration of engineered bacteriophages and bacteria could also be employed. Intensive exploration revealed that if sufficiently controlled approach and proper monitoring were applied, gut microbiota could provide a compelling answer for cardiovascular therapy.

Indexed as

Cardiovascular DiseasesGastrointestinal MicrobiomeProbioticsSynbioticsFecal Microbiota TransplantationHumansPrebioticsPrebiotics

Identifiers

PMID34699042
OpenAlexW3208075223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.